Real-World Data for Lenvatinib in Radioiodine-Refractory Differentiated Thyroid Cancer (RELEVANT): A Retrospective Multicentric Analysis of Clinical Practice in Austria

BACKGROUND: Lenvatinib has proven efficacy in progressive, radioiodine- (RAI-) refractory thyroid cancer (TC). Dose reductions are commonly performed due to decreased tolerability and adverse effects. This retrospective multicenter study analyzed overall survival (OS) and progression-free survival (...

Descripción completa

Detalles Bibliográficos
Autores principales: Rendl, G., Sipos, B., Becherer, A., Sorko, S., Trummer, C., Raderer, M., Hitzl, W., Ardelt, M., Gallowitsch, H. J., Pirich, C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7719524/
https://www.ncbi.nlm.nih.gov/pubmed/33312196
http://dx.doi.org/10.1155/2020/8834148

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7719524/
https://www.ncbi.nlm.nih.gov/pubmed/33312196
http://dx.doi.org/10.1155/2020/8834148

Ejemplares similares